The Filing Desk

Kestra Medical Technologies vs NeuroPace

Kestra Medical Technologies KMTS · NeuroPace NPCE · Health Care Equipment

NeuroPace reported revenue of $100 million in fiscal 2025, about the same as Kestra Medical Technologies' $95 million in fiscal 2026. Kestra Medical Technologies' revenue grew 59.0% in its latest year, and NeuroPace's grew 25.1%. Kestra Medical Technologies had an operating margin of -141.6%, against -16.3% at NeuroPace. Free cash flow was −$117 million at Kestra Medical Technologies and −$11 million at NeuroPace. Their fiscal years end in different months (April 30 and December 31), so the periods don't line up exactly.

Side by side

Kestra Medical TechnologiesNeuroPace
Latest fiscal yearFY2026, Apr 30, 2026FY2025, Dec 31, 2025
Revenue$95M$100M
Revenue growth59.0%25.1%
Revenue growth a year, last 5 years—19.5%
Gross margin51.4%77.2%
Operating margin−141.6%−16.3%
Net margin−138.4%−21.5%
Free cash flow−$117M−$11M
Free cash flow margin−122.6%−11.3%
Return on capital—−81.8%
Net debt to EBITDA——
Dividends and buybacks$0M$50M
Change in diluted share count120.4%12.3%
Last close$26.63$8.14
P/E at the last close——
Insider trades, last 12 monthsbought $199,800, sold $9.3 millionbought $302,102, sold $399,250
Piotroski F-score4 of 95 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kestra Medical TechnologiesNeuroPace
Operating margin
Percent of revenue
Kestra Medical TechnologiesNeuroPace
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kestra Medical TechnologiesNeuroPace

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kestra Medical Technologies and NeuroPace pages.